Angiopoietin-2, BMP-9, EGF, Endoglin, Endothelin-1, FGF-1, FGF-2, Follistatin, G-CSF, HB-EGF, HGF, IL-8, Leptin, PLGF, VEGF-A, VEGF-C, VEGF-D.
Biomarker Research Areas:
Vascular Development, Cancer, Cardiovascular Diseases, Diabetic Ulcers, Macular Degeneration, and Wound Healing.
Multiplex Assay Overview:
The assay service provided by Eve Technologies on their Human Angiogenesis / Growth Factor Array facilitates research on vascular development, cancer, cardiovascular diseases, diabetic ulcers, macular degeneration, and wound healing. This Discovery Assay® measures 17 angiogenesis / growth factor biomarkers simultaneously in a single microwell: Angiopoietin-2, BMP-9, EGF, Endoglin, Endothelin-1, FGF-1, FGF-2, Follistatin, G-CSF, HB-EGF, HGF, IL-8, Leptin, PLGF, VEGF-A, VEGF-C, VEGF-D. The assay is designed for protein analysis in serum, plasma, cell cultures, and tissue homogenates. Other sample types can be tested, however we recommend a pilot run.
Angiogenesis, the development of new vascular networks, is a key process in normal growth and development as well as in wound healing, with homeostasis maintained by a delicate balance of angiogenic factors and inhibitors. Consequently, insufficient or excessive blood vessel growth underlies many diseases, including cardiovascular disease, diabetic ulcers, macular degeneration and cancer. Angiogenesis plays a significant role in tumor growth and metastasis.
In tumors, dysregulated signalling and hypoxic conditions lead to sustained, almost uncontrolled angiogenesis – a necessary component of tumor growth and metastasis. Chronic inflammation mechanisms, such as the production of reactive oxygen species during infection and secretion of pro-inflammatory cytokines can also foster angiogenesis in tumor progression. Angiogenic signalling in tumors is similar to normal angiogenesis, mediated by soluble growth factors, membrane-bound receptors, and cell-cell and cell-matrix interactions. Such signalling
regulates cell migration, which is vital to angiogenesis. However, there are multiple differences between tumor angiogenesis and normal blood vessel formation. Tumor endothelial cells proliferate faster than non-tumor endothelial cells. Tumor vasculature differs from normal vasculature in morphology, enhanced leakiness, and structural abnormalities. Finally, tumor vessels are often not capable of transporting oxygen to and removing waste products from all of the tumor tissues, resulting in frequent tumor cell necrosis.
Intended Sample Type:
Human serum or plasma (EDTA recommended), cell cultures, tissue homogenates and others. A pilot run is recommended for cell cultures, tissue homogenates, and other sample types not listed.
Special Sample Preparation:
Serum and Plasma samples will be diluted 1:3 by Eve Tech to bring protein concentrations within the standard curve range.
Unless otherwise stated our products and services are intended for research use only.
Multiplex Immunoassay analyzed with a BioPlex 200
Angiogenesis Array Assay Kit Source:
Sensitivity, Variation, & Accuracy*Note: %CV is an appropriate measure of quality only for sample that have significant detectable concentrations for a particular analyte. Low concentration / low signal samples can often have a much higher %CV as the signals are at the limitations of the assay and fall within a flat portion of the curve.
% recovery is comparing the observed concentration to the expected concentration of samples spiked with the standard curve cocktail at various concentrations.